Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
This is a single-center randomized phase 2 open-label clinical trial.
Trial Details
- NCT ID
- NCT07710534
- Phase
- PHASE2
- Sponsor
- Virginia Commonwealth University
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Decitabine-cedazuridine plus venetoclax (DEC-C+VEN)
- Azacitidine plus venetoclax (AZA+VEN)
- Locations (sample)
- Richmond, Virginia, United States|37.55376,-77.46026
Key Eligibility Criteria
- Age ≥18 years at time of enrollment
- Diagnosis of one of the following by World Health Organization (WHO) International Consensus Classification (ICC) criteria as determined by local a…
- Relapsed/ refractory acute myeloid leukemia (R/R AML) as defined by ≥5% marrow blasts or unequivocal, measurable extramedullary disease
- High Risk Myelodysplastic Syndrome (HR-MDS) (high/very high risk MDS by Revised International Prognostic Scoring System (IPSS-R) or Molecular Inter…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →